FindTrial
Sign In

BNT162b1

BIOLOGICAL3 trials

Sponsors

BioNTech SE

Conditions

COVID-19Infection ViralInfections, RespiratoryProtection Against COVID-19 and Infections With SARS CoV 2RNA Virus InfectionsSARS-CoV-2SARS-CoV-2 InfectionVaccine Adverse Reaction

Phase 1

A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
CompletedNCT04380701
BioNTech SEInfections, Respiratory, Infection Viral, Protection Against COVID-19 and Infections With SARS CoV 2 +3
Start: 2020-04-23End: 2022-04-13Updated: 2024-07-12
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects
CompletedNCT04523571
BioNTech SESARS-CoV-2
Start: 2020-07-28End: 2021-08-10Updated: 2023-09-18

Phase 2

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
CompletedNCT04368728
BioNTech SECOVID-19, SARS-CoV-2 Infection
Start: 2020-04-29End: 2023-02-10Updated: 2026-03-25

Related Papers

R-index: a standardized representativeness metric for benchmarking diversity, equity, and inclusion in biopharmaceutical clinical trial development.
2025-01-311 citations
Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old.
2023-05-0812 citations
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
2023-04-2125 citations
Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old
Future Virology2023-01-012 citations
Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol
Frontiers in Immunology2022-11-2911 citations
Plain Language Summary of Pfizer-BioNTech BNT162b2 COVID-19 Vaccine Safety in Participants at Least 16 Years Old and Protection Against COVID-19 in Participants at Least 12 Years Old
Future Virology2022-11-25
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial.
2022-09-1412 citations
Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults.
2022-08-31126 citations
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
Emerging Microbes & Infections2022-07-0649 citations
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial.
2022-06-304 citations
Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial
Vaccine2021-12-2454 citations
Assessment of COVID-19 Vaccines in Patients With Lymphoid Malignancies
Oncology Times2021-11-19
Coronavirus disease 2019 vaccine for children in China: when to start? Mandatory or voluntary?
Chinese Medical Journal2021-09-214 citations
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
New England Journal of Medicine2021-09-151521 citations
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
New England Journal of Medicine2021-05-27911 citations
Why Are Children Always Last?
ASA Monitor2021-04-22
BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
2021-02-01599 citations
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
New England Journal of Medicine2020-12-1015106 citations
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
New England Journal of Medicine2020-10-142683 citations
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
2020-08-121153 citations

1 more papers not shown